<DOC>
	<DOCNO>NCT01639794</DOCNO>
	<brief_summary>This observational study look improvement Lower Urinary Tract Symptoms ( LUTS ) Irish men treat Vesitirim™ ( solifenacin ) . Vesitirim™ competitive specific muscarinic receptor antagonist use extensively treatment OAB ( Over Active Bladder ) woman show significant impact urgency , frequency incontinence female . It also indicate symptomatic treatment urgency incontinence and/or increase urinary frequency urgency men . The purpose study evaluate LUTS storage symptom improvement men non neurogenic LUTS prescribe Vesitirim™ . The effect Vesitirim ( solifenacin ) treatment bothersome symptom improvement measure use Over Active Bladder-q Short Form ( OAB-qSF ) Perception Treatment Satisfaction ( TS-VAS ) . The study also help define characteristic male population Ireland treat Vesitirim™ ( solifenacin ) well evaluate effect Vesitirim™ monotherapy combination therapy storage symptom improvement ( urgency , frequency urge incontinence ) use bladder diary IPSS ( International Prostate Symptom Score ) . The study also evaluate effect Vesitirim™ monotherapy combination therapy nocturia use IPSS . The impact LUTS quality life also assess . Data also collect regard adverse drug reaction .</brief_summary>
	<brief_title>Vesitirim™ Men Postmarketing Observational Study</brief_title>
	<detailed_description>This post marketing , non-interventional study ( NIS ) patient treat Vesitirim™ . The decision whether treat Vesitirim™ make treat physician prior entry patient study . The patient inform study write consent obtain prior screen determination eligibility . No study drug supply part study .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Diagnosis nonneurogenic Lower Urinary Tract Symptoms ( LUTS ) bothersome storage disorder define urgency , and/or frequency and/or Urge Urinary Incontinence ( UUI ) discretion Investigator Eligible start Vesitirim™ 5 10mg accord SmPC ( Summary Product Characteristics ) History stress incontinence Active urinary tract infection ( confirm positive urine analysis ) Symptoms suggestive severe Bladder Outlet Obstruction ( BOO ) define Qmax &lt; 10ml/sc and/or PVR &gt; 150ml History know hypersensitivity solifenacin succinate , oxybutynin hydrochloride , anticholinergic lactose , component dosage form allergy , , opinion Investigator contraindicate participation Uncontrolled Diabetes Mellitus History drug and/or alcohol abuse time enrolment History acute urinary retention , severe gastrointestinal obstruction ( include paralytic ileus intestinal atony toxic megacolon severe ulcerative colitis ) , myasthenia gravis , uncontrolled narrow glaucoma swallow anterior chamber deem risk condition Undergoing haemodialysis severe renal impairment moderate hepatic impairment treatment potent CYP3A4 inhibitor History urogenital tumour opinion Investigator preclude participation study Likely participate another study study period 12 week study entry</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>LUTS ( Lower Urinary Tract Symptoms )</keyword>
	<keyword>Overactive Bladder ( OAB ) Vesitirim</keyword>
	<keyword>Solifenacin</keyword>
	<keyword>Anti-muscarinic treatment</keyword>
	<keyword>Cholinergic receptor antagonist</keyword>
	<keyword>Storage Symptom improvement</keyword>
</DOC>